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ABSTRACT
Background: Increased intrahepatic vascular tone in
cirrhosis has been attributed to a decrease of hepatic
nitric oxide (NO) secondary to disturbances in the post-
translational regulation of the enzyme eNOS. NO
scavenging by superoxide (O2
2) further contributes to a
reduction of NO bioavailability in cirrhotic livers.
Aim: To investigate whether removing increased O2
2
levels could be a new therapeutic strategy to increase
intrahepatic NO, improve endothelial dysfunction and
reduce portal pressure in cirrhotic rats with portal
hypertension.
Methods: Adenoviral vectors expressing extracellular
superoxide dismutase (SOD) (AdECSOD) or b-galactosi-
dase (Adbgal) were injected intravenously in control and
CCl4-induced cirrhotic rats. After 3 days, liver O2
2 levels
were determined by dihydroethidium staining, NO
bioavailability by hepatic cGMP levels, nitrotyrosinated
proteins by immunohistochemistry and western blot, and
endothelial function by responses to acetylcholine in
perfused rat livers. Mean arterial pressure (MAP) and
portal pressure were evaluated in vivo.
Results: Transfection of cirrhotic livers with AdECSOD
produced a significant reduction in O2
2 levels, a
significant increase in hepatic cGMP, and a decrease in
liver nitrotyrosinated proteins which were associated with
a significant improvement in the endothelium-dependent
vasodilatation to acetylcholine. In addition, in cirrhotic
livers AdECSOD transfection produced a significant
reduction in portal pressure (17.3 (SD 2) mm Hg vs 15
(SD 1.6) mm Hg; p,0.05) without significant changes in
MAP. In control rats, AdECSOD transfection prevents the
increase in portal perfusion pressure promoted by an
ROS-generating system.
Conclusions: In cirrhotic rats, reduction of O2
2 by
AdECSOD increases NO bioavailability, improves intrahe-
patic endothelial function and reduces portal pressure.
These findings suggest that scavenging of O2
2 might be a
new therapeutic strategy in the management of portal
hypertension.
Increased intrahepatic vascular resistance to portal
blood flow is the main cause of portal hypertension
in cirrhosis and is the result of both structural
changes and an increase in the hepatic vascular tone
within the cirrhotic liver.1 Sinusoidal endothelial cell
dysfunction, characterised by impaired endothe-
lium-dependent vasodilation, appears to be an
important mechanism of the increased vascular
tone of cirrhotic livers and has been attributed
to increased release of cyclooxygenase-1-derived
vasoconstrictive prostanoids2 and to reduced nitric
oxide (NO) bioavailability.3–5
Reduced NO bioavailability within cirrhotic
livers is the result of a decrease in endothelial NO
synthase (eNOS) activity due to alterations on its
post-translational regulation.6 7 However, recent
data from our group have demonstrated that
scavenging of NO by the increased levels of
superoxide (O2
2) found in cirrhotic livers contri-
butes further to a reduction of NO bioavailability.
This study suggests that removing increased O2
2
levels in cirrhotic livers could be a new therapeutic
strategy for improving intrahepatic NO bioavail-
ability, reducing intrahepatic resistance and
improving portal hypertension.8
Increased production of reactive oxidative spe-
cies (ROS) in cirrhotic livers was shown to be the
consequence of an increased production by several
enzymatic systems (such as cyclooxygenase and
xanthine oxidase)8 9 but, in addition, to a reduced
expression and activity of superoxide dismutase
(SOD), a critical enzyme that metabolises O2
2.8 10
Gene transfer of SOD has been shown to protect
against oxidative stress and to improve endothe-
lium-dependent relaxation in several situations,
including myocardial infarction,11 liver transplanta-
tion,12 hypertension,13 14 diabetes15 and ageing.16
Therefore, the present study was aimed at investi-
gating whether adenovirus-mediated gene transfer of
SOD is able to decrease O2
2 levels, increase NO
bioavailability, and, consequently, improve hepatic
endothelial dysfunction and reduce portal pressure in
rats with cirrhosis and portal hypertension.
MATERIAL AND METHODS
Induction of cirrhosis
Cirrhosis was induced in male Wistar rats (175–
200 g) by inhalation of carbon tetrachloride (CCl4)
three times a week. Phenobarbital (0.3 g/l) was
added to the drinking water as previously described.17
When cirrhotic rats had developed ascites, 12–
15 weeks after inhalation of CCl4, administration
of CCl4 and phenobarbital was stopped and experi-
ments were performed 1 week later. Control animals
received only phenobarbital. The animals were kept
in environmentally controlled animal facilities at the
Institut d’Investigacions Biome`diques August Pi i
Sunyer (IDIBAPS).
Adenoviral vectors and gene transfer in vivo
Replication-deficient adenoviral constructs, under
the control of the human cytomegalovirus (CMV)
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promoter/enhancer were used. One, expressing human extra-
cellular SOD (AdECSOD) constructed by Dr Chu, was provided
by the Vector Core at the University of Iowa, and the other,
expressing b-galactosidase (Adbgal), was provided by Dr CB
Newgard (Duke University, Durham, North Carolina, USA).
The viruses were propagated in the human embryonic kidney
(HEK) 293 cell line. Purification and titres were determined
using established protocols.18 These ECSOD adenoviruses are
capable of infecting and expressing enzymatically active SOD in
endothelial cells.13
Gene transfer in vivo was performed in rats anaesthetised
with isoforane (Abbott, Madrid, Spain) (2–5%). The AdECSOD
or the control virus, Adbgal (561011 particles in 3% sucrose in
phosphate-buffered saline) were injected into the penile vein of
control and cirrhotic animals and all studies were performed
3 days later. Three days after intravenous injection of
AdECSOD (561011 particles), plasma alanine aminotransferase
was not modified and no gross changes were revealed in the
histological examination of the liver.14
ECSOD protein expression
To confirm the expression of human ECSOD in transfected
livers, immunohistochemistry and western blot for ECSOD
were performed.
Immunohistochemistry was performed in paraffin-embedded
liver sections (8 mm thick) from control and cirrhotic rats, after
transfection with AdECSOD or Adbgal, as previously described
(n = 4 animals per group).14 Immunohistochemistry was per-
formed using a polyclonal rabbit anti-human ECSOD antibody
that specifically recognises human ECSOD (1:500, 4uC, over-
night), which was a generous gift from Professor JD Crapo
(National Jewish Medical Research Center, Denver, Colorado,
USA), followed by horseradish peroxidase (HRP)-conjugated
goat–anti-rabbit immunoglobulin G (IgG) antibody (1:200).
Binding was visualised using 39,39-diaminobenzadine (DAB)
(Dako, Carpinteria, California, USA) and 0.01% H2O2 as the
chromogen. For the negative control, phosphate-buffered saline
was used instead of the primary antibody. All sections were air
dried, counter-stained with haematoxylin and examined by
light microscopy using a 610 objective (Axiovert 135; Carl
Zeiss, Go¨ttingen, Germany).
Immunoreactivity for human ECSOD was quantified with an
image-analysis system (AxioVision Release 4.6.3; Carl Zeiss)
that allows a semiquantitative grading from 0 to 3 (0, minimal
staining; 1, weak staining; 2, moderate staining; and 3, strong
staining). Preparations were blindly assessed by the same
investigator (BL).19
Western blot was performed in frozen liver samples from
cirrhotic rats transfected with AdECSOD (n = 6) or Adbgal
(n = 4). Samples were crushed to a powder and subsequently
homogenised in Triton–lysis buffer as previously described.20
Aliquots from each sample containing equal amounts of
protein (20 mg) were run on a 12% sodium dodecyl sulfate–
polyacrylamide gel, and transferred to a nitrocellulose mem-
brane. After transfer, the blots were subsequently blocked for
1 h with Tris-buffered saline containing 0.05% (vol/vol) Tween
20 and 5% (wt/vol) nonfat dry milk and probed with a rabbit
anti-extracellular SOD (1 mg/ml) antibody (ECSOD; Stressgen,
Victoria, British Columbia, Canada) overnight at 4uC followed
by incubation with anti-rabbit HRP-conjugated secondary
antibody (1:10 000, 1 h, room temperature; Stressgen).
Protein expression was determined by densitometric analysis
using the Science Lab Image Gauge (Fuji Photo Film, Du¨sseldorf,
Figure 1 (A) Representative histological images of liver tissues
immunostained for human extracellular superoxide dismutase (ECSOD)
from control (CT) and cirrhotic (CH) rats, 3 days after intravenous
injection of adenoviral vectors expressing either b-galactosidease
(Adbgal) (a and c) or ECSOD (AdECSOD) (b and d) (561011 viral particles
per rat) (n = 4 animals per group). (B) Top. Representative western blot
of ECSOD in livers from cirrhotic (CH) rats transfected with Adbgal or
AdECSOD. Bottom. Densitometry analysis of ECSOD expression in
cirrhotic rat livers transfected with Adbgal (n = 4) or AdECSOD (n = 6)
(normalised to glyceraldehyde-3-phosphate dehydrogenase (GAPDH);
normalised arbitrary units (AU) (SEM). *p,0.05 vs CH Adbgal).
Table 1 Semiquantitative data of extracellular superoxide dismutase
immunohistochemistry studies
Group
Score
Staging score0 (%) 1 (%) 2 (%) 3 (%)
CT Adbgal 100 0 0 0 0
CT AdECSOD 0 0 30 70 2.7 (0.15)*
CH Adbgal 0 0 0 0 0
CH AdECSOD 0 0 70 30 2.3 (0.15){
Data are mean (SEM). n = 4 animals per group.
*p,0.05 vs CTAdbgal; {p,0.05 vs CHAdbgal.
AdECSOD, adenoviral vectors expressing extracellular superoxide dismutase; Adbgal,
adenoviral vectors expressing b-galactosidase; CH, cirrhotic rats; CT, control rats.
Hepatology
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Germany). After stripping, blots were assayed for glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH; Santa Cruz
Biotechnology, Santa Cruz, California, USA) expression as
standardisation of sample loading. Quantitative densitometric
values of all proteins were normalised to GAPDH.
Measurement of O2
2 content in liver tissue
The generation of O2
2 in situ was evaluated in fresh liver
cryosections taken from nine cirrhotic livers (three transfected
with AdECSOD, three with Adbgal or three treated with vehicle
(3% sucrose in phosphate-buffered saline) and three control
livers with the oxidative fluorescent dye dihydroethidium
(DHE) (Molecular Probes, Eugene, Oregon, USA). Ten fields
for each animal, using a 640 objective, were chosen at random
and quantified as previously described.8 DHE specifically reacts
with intracellular and extracellular O2
221 and is converted to the
red fluorescent compound ethidium bromide (EtBr), which then
binds irreversibly to double-stranded DNA and appears as
punctate nuclear staining.
Nitric oxide bioavailability
Measurements of cGMP, a marker of NO bioavailability, were
performed in control (n = 5 per group) and cirrhotic (n = 7 per
group) rat liver homogenates transfected with AdECSOD or
Adbgal using an enzyme immunoassay (Cayman Chemical,
Ann Arbor, Michigan, USA), as previously described.20
Nitrotyrosine protein detection
Immunohistochemistry for nitrotyrosine (NT) was performed
in paraffin-embedded liver sections (8 mm thick) from cirrhotic
rats, transfected with AdECSOD (n = 3) or Adbgal (n = 3),
using a polyclonal rabbit anti-nitrotyrosine antibody (Upstate,
Lake Placid, New York, USA) (1:100 dilution), as described
above. A semiquantitative analysis was performed as previously
described.
In addition, in cirrhotic rat livers transfected with AdECSOD
(n = 4) or Adbgal (n = 4) protein nitrotyrosination was
determined by western blot using a mouse anti-nitrotyrosine
(1 mg/ml) antibody (Cayman Chemical) as previously
described.8
After stripping, blots were assayed for GAPDH (Santa Cruz
Biotechnology) expression as standardisation of sample loading.
Quantitative densitometric values of all proteins were normal-
ised to GAPDH.
Effects on portal perfusion pressure and superoxide levels
promoted by the superoxide generating system NADPH/NADPH
oxidase in control rat livers
Control livers transfected with Adbgal (n = 5) or AdECSOD
(n = 7) were isolated and perfused by a flow-controlled
perfusion system as previously described.17 Briefly, livers were
perfused with Krebs buffer in a recirculation fashion with a
total volume of 100 ml at a constant flow rate of 35 ml/min
with an ultrasonic flow probe (T201; Transonic System, Ithaca,
New York, USA). A pressure transducer was placed immediately
Figure 2 (A) Representative confocal
fluorescence microscopy images of in situ
detection of superoxide with the oxidative
dye dihydroethidium (DHE) in fresh liver
sections from control (CT) and cirrhotic
(CH) rats 3 days after adenoviral vectors
expressing extracellular superoxide
dismutase (AdECSOD), adenoviral vectors
expressing b-galactosidase (Adbgal)
transfection or vehicle (Veh). (B) DHE
fluorescence intensity (% vs CT Veh) of
three independent experiments. *p,0.05
vs CT Veh; {p,0.05 vs CH Adbgal.
Figure 3 Intrahepatic cGMP levels in control (CT) and cirrhotic (CH)
rats transfected with adenoviral vectors expressing b-galactosidase
(Adbgal) or adenoviral vectors expressing extracellular superoxide
dismutase (AdECSOD). Data are expressed as normalised mean (SEM).
*p,0.05 vs CT Adbgal.
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before the portal inlet cannula to continuously monitor portal
flow and portal perfusion pressure. The flow probe and the
pressure transducers were connected to a Powerlab (4SP) linked
to a computer using the Chart v5.0.1 for Windows software
(ADInstruments, Mountain View, Louisiana, USA).
The perfused rat liver preparation was allowed to stabilise for
20 min before nicotinamide adenine dinucleotide phosphate
(NADPH 100 mmol/l; Applichem, Darmstadt, Germany), the
substrate of NADPH oxidase, or its vehicle (Krebs buffer) was
added. The gross appearance of the liver, portal perfusion
pressure, and buffer pH (7.4 (SD 0.1)) were observed during this
period. Responses to NADPH were calculated as a per cent
change in portal perfusion pressure.
Measurements of O2
2 in liver tissue were evaluated as
described above in two independent experiments.
Splanchnic and systemic in vivo haemodynamics of control and
cirrhotic rats
Control (n = 6) and cirrhotic (n = 10) rats were anaesthetised
with ketamine hydrochloride (100 mg/kg intraperitoneally;
Merial Laboratories, Barcelona, Spain) plus midazolam (5 mg/
kg intramuscularly; Laboratorios Reig Jofre´, Barcelona, Spain).
The temperature was maintained at 37 (SD 0.5)uC. A
tracheotomy was performed to maintain adequate ventilation.
The femoral artery and ileocolic vein were cannulated to
continuously monitor mean arterial pressure (MAP; mm Hg)
and portal pressure (mm Hg). Measurements were taken after
20 min of stabilisation.
Evaluation of endothelial function in control and cirrhotic
perfused rat livers
After haemodynamic measurements in vivo, livers were quickly
isolated and perfused by a flow-controlled perfusion system as
described above. The perfused rat liver preparation was allowed
to stabilise for 20 min before vasoactive substances were added.
The intrahepatic microcirculation was preconstricted by adding
the a1-adrenergic agonist methoxamine (Sigma, St Louis,
Missouri, USA) to the reservoir to achieve a final concentration
of 1024 mol/l. After 5 min, concentration–response curves to
cumulative doses of acetylcholine, 1027, 1026 and 1025 mol/l
(Sigma), were evaluated. The concentration of acetylcholine
was increased by one log unit every 1.5 min interval. Responses
to acetylcholine were calculated as per cent change in portal
perfusion pressure, as previously described.4 22
Statistical analysis
Statistics were performed using the SPSS 14.0 for Windows
statistical package. All results are expressed as mean (SD) unless
otherwise specified in the figure legends. Comparisons between
two groups were performed with the Student t test for unpaired
data. The ANOVA test for repeated measurements was used
when appropriate. Significance was established at the 0.05 level.
RESULTS
Effect of ECSOD gene transfer on O2
2 levels and NO
bioavailability in rat livers
Control and cirrhotic rat livers transfected with AdECSOD
effectively expressed human ECSOD, as shown by semiquanti-
tative analysis of ECSOD immunostainings (fig 1A and table 1)
and western blot (fig 1B) in comparison to control and cirrhotic
rat livers transfected with Adbgal.
Superoxide levels were significantly higher in cirrhotic rat
livers than in control rat livers (fig 2). AdECSOD, but not
Adbgal, transfection produced a marked and significant reduc-
tion of O2
2 levels in cirrhotic rat livers to a point that was
similar to those found in control livers (fig 2). cGMP levels, a
surrogate marker of NO bioavailability, were significantly lower
in cirrhotic than in control livers (fig 3). cGMP content did not
change after AdECSOD transfection in the control livers but
significantly increased in those cirrhotic rat livers transfected
with AdECSOD. In addition, in cirrhotic rat livers AdECSOD
transfection produced a reduction of nitrotyrosinated proteins,
as shown by semiquantitative analysis of nitrotyrosine immu-
nostaining (fig 4A and table 2) and western blot analysis (fig 4B).
Figure 4 (A) Representative histological images of liver tissues
immunostained for nitrotyrosine from cirrhotic (CH) rats transfected with
adenoviral vectors expressing b-galactosidase (Adbgal) or adenoviral
vectors expressing extracellular superoxide dismutase (AdECSOD) (three
different animals for each treatment). (B) Top. Representative western
blot of nitrotyrosinated proteins (3-NT) of livers from cirrhotic (CH) rats
transfected with Adbgal or AdECSOD. Bottom. Densitometry analysis of
nitrotyrosinated proteins in cirrhotic rat livers transfected with Adbgal
(n = 4) or AdECSOD (n = 4) (normalised to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH); normalised arbitrary units (AU) (SEM)).
Table 2 Semiquantitative data of nitrotyrosine immunohistochemistry
studies
Group
Score
Staging score0 (%) 1 (%) 2 (%) 3 (%)
CH Adbgal 0 25.00 33.33 41.67 2.17 (0.24)
CH AdECSOD 0 66.67 33.33 0 1.33 (0.14)*
Data are mean (SEM). n = 4 animals per group.
*p,0.05 vs CHAdbgal.
Adbgal, adenoviral vectors expressing b-galactosidase; AdECSOD, adenoviral vectors
expressing extracellular superoxide dismutase; CH, cirrhotic rats.
Hepatology
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Effects on portal perfusion pressure and superoxide levels
promoted by the superoxide generating system NADPH/NADPH
oxidase in control rat livers transfected with AdECSOD
NADPH produced a significant increase in hepatic O2
2 levels
and in portal perfusion pressure (7 (SD 5)% vs 0.6 (SD 0.8)%
increase, p,0.05) in control rats transfected with Adbgal in
comparison to those treated with vehicle. AdECSOD transfec-
tion attenuated both the increase in hepatic O2
2 levels and the
elevation of portal perfusion pressure produced by NADPH (2
(SD 2)% increase in portal perfusion pressure, p,0.05 vs
Adbgal+NADPH) (fig 5B).
Effects of ECSOD gene transfer on portal pressure in control and
cirrhotic rats
The cirrhotic rats transfected with Adbgal showed arterial
hypotension and portal hypertension when compared with
those control rats transfected with Adbgal.
MAP or portal pressure was not significantly different in
control rats transfected with AdECSOD or Adbgal (fig 6A).
However, in contrast, cirrhotic rats transfected with AdECSOD
had significantly lower portal pressure than those transfected
with Adbgal (15 (SD 1.6) mm Hg vs 17.3 (SD 2) mm Hg;
p,0.05), without significant differences in MAP (97 (SD
17) mm Hg vs 102 (SD 15) mm Hg; not significant) (fig 6B).
Effect of ECSOD gene transfer on endothelial function in rat
livers
To further characterise the effects of AdECSOD transfection on
the liver vasculature, control and cirrhotic rat livers transfected
with AdECSOD or Adbgal were isolated and perfused. Baseline
portal perfusion pressure was significantly greater in Adbgal
cirrhotic rat livers than in Adbgal control rat livers (10.9 (SD
2.3) vs 4.8 (SD 1.1) mm Hg; p,0.0001). In addition, in
accordance with results obtained from previous studies,4 22
Figure 5 (A) Top. Representative
confocal fluorescent microscopy images
of in situ detection of O2
2 with
dihydroethidium (DHE) in fresh liver
sections from control (CT) rats
transfected with adenoviral vectors
expressing extracellular superoxide
dismutase (AdECSOD) or adenoviral
vectors expressing b-galactosidase
(Adbgal) in response to nicotinamide
adenine dinucleotide phosphate (NADPH)
or its vehicle (Veh). Bottom. DHE
fluorescence intensity (% vs CT Adbgal
Veh). ({p,0.05 vs CT Adbgal Veh;
*p,0.05 vs CT Adbgal NADPH).
(B) Portal perfusion pressure change (PP)
after NADPH or its vehicle, in control (CT)
rats transfected with Adbgal (n = 5) or
AdECSOD (n = 7). Results are expressed
as mean (SEM). {p,0.05 vs CT Adbgal
Veh; 1p,0.05 vs CT Adbgal NADPH.
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Adbgal cirrhotic livers exhibited a significantly higher portal
perfusion pressure response to methoxamine (20.9 (SD 3 vs 10.1
(SD 3.8) mm Hg; p,0.001) and a lower vasodilator response to
acetylcholine than Adbgal control livers (fig 7). In the control
livers, AdECSOD transfection did not significantly modify the
portal perfusion pressure response to methoxamine or the
vasodilator response to acetylcholine (fig 7A). However, in
cirrhotic livers, AdECSOD transfection reduced the portal
perfusion pressure response to methoxamine (18.3 (SD 3) vs
20.9 (SD 3) mm Hg in Adbgal cirrhotic livers; p = 0.06) and
significantly improved the vasodilatory response to acetylcho-
line (fig 7B).
DISCUSSION
In cirrhosis, increased resistance to portal blood flow is
determined by structural changes in the liver and is further
aggravated by an increase in hepatic vascular tone.1 23 This latter
component, which results from the reduction of hepatic NO
bioavailability4 24 and an increased production of circulating and
local vasoconstrictors,25–28 is theoretically amenable to treatment
with vasodilators.29
Attempts to correct the intrahepatic NO deficiency have been
based on either over-expressing NOS by transfecting the liver
with adenovirus encoding eNOS,30 31 nNOS,32 or constitutively
active Akt,33 by administration of NO donors,34 35 or by
enhancing eNOS activity by simvastatin (a 3-hydroxy-3-
methyl-glutaryl-CoA (HMG–CoA) reductase inhibitor)20 36 or
by the eNOS co-factor tetrahydrobiopterin.6 These strategies,
which effectively increased NO production, have been shown to
be associated, in most cases, with a slight reduction in portal
pressure. This paradox may, at least in part, be due to the fact
that the increased ROS levels observed in cirrhotic livers could
lead to NO inactivation attenuating the efficacy of those
strategies aimed at increasing NO synthesis.8–10
For this reason, the goal of the present study was to pursue
the strategy of increasing NO bioavailability not by increasing
its production but by reducing its scavenging by O2
2. The local
concentration of SOD is a determinant of O2
2 and therefore we
tested the hypothesis that, by increasing dismutation of O2
2
by SOD, NO bioavailability could be increased by reducing O2
2
levels.
We used the gene transfer approach, using recombinant
replication-deficient adenovirus vectors carrying the human
ECSOD gene, in order to reduce O2
2 levels because gene transfer
causes stable expression of protective enzymes and proteins.37
Human ECSOD protein was used because it is tetrameric and
glycosylated38 and thus it has a longer plasma half-life than
intracellular CuZnSOD. In addition, ECSOD contains a
positively charged heparin-binding domain, which aids the
binding of ECSOD to heparin sulfate proteoglycans on the cell
surface and in the extracellular matrix. ECSOD in these
extracellular locations is highly effective in preventing the
scavenging of NO when it diffuses from sinusoidal endothelial
cells to hepatic stellate cells.39 One possible concern of our
approach could be the accumulation of hydrogen peroxide,
which can act as a vasoconstrictor.40 However, the results of the
present study support the hypothesis that, once produced,
hydrogen peroxide is rapidly decomposed to water and oxygen
by the action of catalase, an enzyme mostly produced in the
liver and which constitutes 0.5–1% of the total protein in this
organ.41
Figure 6 Mean arterial pressure (MAP) and portal pressure (PP) in (A),
control (CT) (n = 6) and (B) cirrhotic (CH) (n = 10) rats 3 days after
transfection with adenoviral vectors expressing b-galactosidase
(Adbgal) or adenoviral vectors expressing extracellular superoxide
dismutase (AdECSOD). Results are expressed as mean (SEM). *p,0.05
vs Adbgal.
Figure 7 Vasorelaxation to
acetylcholine (Ach) in (A) control (CT,
n = 6) or (B) cirrhotic (CH, n = 10) rat
livers 3 days after adenoviral infection
with adenoviral vectors expressing
extracellular superoxide dismutase
(AdECSOD) or adenoviral vectors
expressing b-galactosidase (Adbgal).
Results are expressed as mean (SEM).
PP, portal pressure.
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Cirrhotic rat livers showed an increased O2
2 content in
comparison to control rat livers. Superoxide levels were similar
in cirrhotic rats livers treated with vehicle or transfected with
Adbgal, discarding a significant effect of adenoviral transfection
increasing hepatic O2
2 per se.
As shown by immunohistochemical and western blot
analysis, intravenous administration of AdECSOD resulted in
effective transgene expression either in control or cirrhotic rat
livers. This resulted in a marked reduction in O2
2 and enhanced
NO bioavailability in cirrhotic livers which were then associated
with a reduction in intrahepatic nitrotyrosinated proteins, a
well recognised marker of the reaction of O2
2 with NO. For the
first time, these findings support, in vivo, the concept that
reducing increased hepatic O2
2 levels in cirrhosis can improve
hepatic NO bioavailability, which has recently been demon-
strated in vitro.8
In accordance with the working hypothesis, increasing NO
bioavailability by AdECSOD transfection improved the
impaired vasorelaxation to the endothelium-dependent vasodi-
lator acetylcholine observed in cirrhotic rat livers and, more
importantly, promoted a significant reduction of portal pressure
in vivo. Reduction in portal pressure was probably due to the
improvement of the hepatic vascular bed to vasodilatory stimuli
and the attenuation of the hyper-response to vasoconstrictors.
However, we can not completely discard the suggestion that a
possible reduction in portal blood flow could also contribute. It
is important to note that AdECSOD transfection did not
modify MAP, and this may be the result of a relatively targeted
effect of SOD on the liver microcirculation. This would be a
theoretical advantage over other non-selective strategies aimed
at increasing NO bioavailability, which may produce deleterious
effects worsening the hyperdynamic syndrome found in
cirrhosis.42 This possibility seems reasonable because previous
studies in rodents have shown that approximately 90% of the
adenoviral vector is localised in the liver, both in animals with
normal liver function43 and in CCl4-induced cirrhotic rats.
Although transduction efficiency is reduced in cirrhosis,
expression is nevertheless of high magnitude,44 45 and the liver
is still the main adenoviral target.46
Reduction in portal pressure averaged 13.3% on magnitude.
This is similar to that observed in other studies aimed at reducing
portal pressure in cirrhotic rats through other strategies, such as
the administration of non-selective beta-blockers.47
In conclusion, this study provides evidence, for the first time
in vivo, that decreasing hepatic O2
2 levels by increasing SOD
activity (ie, an antioxidant treatment) may represent an
effective strategy to improve NO bioavailability within the
liver and therefore, strongly supports the possibility that
antioxidant therapy might be an attractive proposition to treat
portal hypertension in cirrhosis.
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ANSWER
From the question on page 67
Skin biopsy confirmed the diagnosis of Sweet’s syndrome (SS; inflammatory infiltrate with
numerous neutrophils). Azathioprine was stopped and corticotherapy led to a spectacular clinical
improvement after 2 days (neutrophils = 76109/l and complete healing of cutaneous lesions).
The patient was discharged on prednisolone at a dose of 60 mg/day for 2 weeks, tapered during
3 weeks. As SS could be associated with inflammatory bowel disease, azathioprine was
reintroduced 1 month later followed by a clinical relapse of the skin lesions, leading to its
definitive withdrawal with favourable outcome.
SS is an acute, febrile neutrophilic dermatosis that includes the following diagnostic criteria:
abrupt onset of painful, erythematous papules and plaques, histopathological evidence of a dense
neutrophilic infiltrate without leucocytoclastic vasculitis and an excellent response to
glucocorticoid. The main aetiologies of SS are idiopathic, inflammatory or neoplastic diseases.1
Some drugs could induce SS (granulocyte colony-stimulating factor, vaccine, all trans retinoic
acid). A few cases of azathioprine-induced SS have been reported in the literature.1–4
The prompt recognition of this association is important to allow the withdrawal of
azathioprine and the initiation of corticotherapy to cure the condition.
Patient consent: Obtained.
Gut 2009;58:125. doi:10.1136/gut.2008.156737a
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